Hugel, Inc. (KOSDAQ:145020)
South Korea · Delayed Price · Currency is KRW | Market Cap | 2.84T -24.4% |
| Revenue (ttm) | 425.11B +14.0% |
| Net Income | 140.87B +3.7% |
| EPS | 12,820.16 +6.9% |
| Shares Out | 10.80M |
| PE Ratio | 20.51 |
| Forward PE | 20.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,670 |
| Average Volume | 38,023 |
| Open | 261,500 |
| Previous Close | 263,000 |
| Day's Range | 252,500 - 264,500 |
| 52-Week Range | 208,500 - 392,000 |
| Beta | 0.58 |
| RSI | 45.96 |
| Earnings Date | May 4, 2026 |
About Hugel
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years o... [Read more]
Financial Performance
In 2025, Hugel's revenue was 425.11 billion, an increase of 13.96% compared to the previous year's 373.05 billion. Earnings were 140.87 billion, an increase of 3.72%.
Financial StatementsNews
Hugel hits record net sales, operating profit in Q3
- Net sales registered KRW105.1 billion and operating profit achieved KRW53.4 billion , up 23.9% and 54.5% on-year, respectively - Net sales of toxin rose 41% on-year, thanks to initial shipment to th...